Randomized Trialhigh evidence
The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.
The lancet. Gastroenterology & hepatology·July 21, 2026·PMID 42480572
Why it mattersRapid liver fat reduction is a key early efficacy signal in MASH, and DD01’s dual agonism may offer metabolic benefits beyond GLP-1 alone. For specialists managing MASLD/MASH, these 12-week data support further investigation of DD01 as a potential disease-modifying therapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled